Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Adc Therapeutics Sa's Business Segments
Adc Therapeutics Sa's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 21
Regions Reported
1
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 21 | 100% |
Revenue Share by Region - Q1 FY2026
- EMEA3.9%
Revenue by Geographic Region - Q1 FY2026
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| EMEA | $ 1 | 3.9% |
Revenue by Product & Service Category - Q1 FY2026
- Product96.1%
- Royalty Revenue3.9%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 20 | 96.1% |
| Royalty Revenue | $ 1 | 3.9% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Adc Therapeutics Sa
We are a leading global supplier of broadband network equipment, software and
systems integration services that enable communications service providers to deliver
high-speed Internet, data, video and voice services to consumers and businesses
worldwide. Telephone companies, cable television operators, Internet and data
service providers, wireless service providers and other communications service
providers are building and upgrading the broadband network infrastructure required
to offer high-speed Internet access as well as data, video, telephony and other
interactive multimedia services. Our product offerings and development efforts
are focused on increasing the speed and efficiency of the last mile/kilometer
portion of broadband communications networks, and our product and service offerings
help connect communications service providers' offices to businesses and end users'
homes as well as to wireless communications devices.
ADC Therapeutics SA is a biotechnology company focused on developing and commercializing innovative antibody-drug conjugates (ADCs) for the treatment of cancer. The company specializes in targeting specific cancer cells while sparing normal cells, thereby minimizing side effects and enhancing therapeutic efficacy. Below is a comprehensive overview of the segments, products, and services offered by ADC Therapeutics SA:
Segments
1. Oncology Division: This division focuses on developing therapies for various cancers, leveraging the unique technology of ADCs that combines antibodies with cytotoxic drugs.
2. Research and Development: ADC Therapeutics invests significantly in R&D to innovate and improve therapeutic methods that target oncological diseases through its proprietary ADC technology platform.
3. Clinical Trials: The company is involved in conducting clinical trials across different phases (Phase I, II, and III) to evaluate the safety and efficacy of its ADC-based therapies.
Products
1. Antibody-Drug Conjugates (ADCs): ADC Therapeutics has developed various ADCs, which are a key product line aimed at treating hematological malignancies and solid tumors. Prominent examples include:
- Loncastuximab tesirine (Zynlonta): This is an ADC targeting CD19, primarily indicated for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It is designed to deliver a cytotoxic agent directly to the cancer cells while sparing healthy cells.
- Camtuzumab Etoseco (ADCT-301): Targeting CD25, this ADC is being investigated for the treatment of hematological malignancies and holds promise in clinical settings, particularly for patients with lymphocytic leukemias.
- ADCT-602: This is another promising ADC targeting CD19, which is being evaluated in clinical trials for its efficacy in treating acute lymphoblastic leukemia (ALL).
2. Development Pipeline: ADC Therapeutics also maintains a strong pipeline of potential ADC products in various stages of clinical development, targeting specific cancers and diverse mechanisms of action.
Services
1. Clinical Development Services: ADC Therapeutics provides clinical development expertise, including the design and management of clinical trials. The services include protocol development, site selection, patient recruitment strategies, and regulatory support.
2. Manufacturing and Technology Transfer: The company offers end-to-end manufacturing capabilities for ADCs, from initial development through to scale-up and commercial production. This includes transferring technology and processes to ensure the smooth production of high-quality ADCs.
3. Regulatory Affairs Support: ADC Therapeutics assists clients in navigating the complex regulatory environment regarding clinical trial applications and marketing authorization submissions for innovative ADC therapies.
4. Partnership Opportunities: The company engages in strategic partnerships with pharmaceutical and biotechnology firms to co-develop ADCs aiming to leverage complementary expertise and resources.
5. Consultancy Services: ADC Therapeutics offers consultancy services related to oncology drug development and ADC-specific strategies, which include market analysis, competitive landscape evaluations, and development of clinical plans.
6. Patient Support Programs: To enhance patient adherence and management, ADC Therapeutics may collaborate with healthcare providers to create educational programs about their therapies and establish frameworks for patient monitoring.
Summary
ADC Therapeutics SA stands at the forefront of cancer treatment through its groundbreaking research and development of antibody-drug conjugates. With a robust portfolio of innovative ADCs and comprehensive services spanning clinical development to manufacturing, the company is dedicated to improving patient outcomes in oncology. The integration of targeted therapy designs with sophisticated delivery mechanisms exemplifies its commitment to advancing the field of cancer therapeutics.
Segments
1. Oncology Division: This division focuses on developing therapies for various cancers, leveraging the unique technology of ADCs that combines antibodies with cytotoxic drugs.
2. Research and Development: ADC Therapeutics invests significantly in R&D to innovate and improve therapeutic methods that target oncological diseases through its proprietary ADC technology platform.
3. Clinical Trials: The company is involved in conducting clinical trials across different phases (Phase I, II, and III) to evaluate the safety and efficacy of its ADC-based therapies.
Products
1. Antibody-Drug Conjugates (ADCs): ADC Therapeutics has developed various ADCs, which are a key product line aimed at treating hematological malignancies and solid tumors. Prominent examples include:
- Loncastuximab tesirine (Zynlonta): This is an ADC targeting CD19, primarily indicated for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It is designed to deliver a cytotoxic agent directly to the cancer cells while sparing healthy cells.
- Camtuzumab Etoseco (ADCT-301): Targeting CD25, this ADC is being investigated for the treatment of hematological malignancies and holds promise in clinical settings, particularly for patients with lymphocytic leukemias.
- ADCT-602: This is another promising ADC targeting CD19, which is being evaluated in clinical trials for its efficacy in treating acute lymphoblastic leukemia (ALL).
2. Development Pipeline: ADC Therapeutics also maintains a strong pipeline of potential ADC products in various stages of clinical development, targeting specific cancers and diverse mechanisms of action.
Services
1. Clinical Development Services: ADC Therapeutics provides clinical development expertise, including the design and management of clinical trials. The services include protocol development, site selection, patient recruitment strategies, and regulatory support.
2. Manufacturing and Technology Transfer: The company offers end-to-end manufacturing capabilities for ADCs, from initial development through to scale-up and commercial production. This includes transferring technology and processes to ensure the smooth production of high-quality ADCs.
3. Regulatory Affairs Support: ADC Therapeutics assists clients in navigating the complex regulatory environment regarding clinical trial applications and marketing authorization submissions for innovative ADC therapies.
4. Partnership Opportunities: The company engages in strategic partnerships with pharmaceutical and biotechnology firms to co-develop ADCs aiming to leverage complementary expertise and resources.
5. Consultancy Services: ADC Therapeutics offers consultancy services related to oncology drug development and ADC-specific strategies, which include market analysis, competitive landscape evaluations, and development of clinical plans.
6. Patient Support Programs: To enhance patient adherence and management, ADC Therapeutics may collaborate with healthcare providers to create educational programs about their therapies and establish frameworks for patient monitoring.
Summary
ADC Therapeutics SA stands at the forefront of cancer treatment through its groundbreaking research and development of antibody-drug conjugates. With a robust portfolio of innovative ADCs and comprehensive services spanning clinical development to manufacturing, the company is dedicated to improving patient outcomes in oncology. The integration of targeted therapy designs with sophisticated delivery mechanisms exemplifies its commitment to advancing the field of cancer therapeutics.